← Search & browse all drugs
GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists
alfuzosin
G04CA01
Forms & Strengths
- Extended-release tablets: 10 mg
Adult Dosing
- Benign prostatic hyperplasia: 10 mg orally once daily, taken immediately after the same meal each day
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)
Mechanism of Action
- Selective alpha-1 adrenergic receptor antagonist in the lower urinary tract
- Relaxes smooth muscle of the prostate bladder neck and urethra
- Improves urine flow and reduces BPH symptoms
Contraindications
- Known hypersensitivity to alfuzosin or any component of the product
- Moderate or severe hepatic impairment (Child-Pugh class B or C)
- Concomitant administration of potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir)
Adverse Reactions
- Dizziness
- Fatigue
- Headache
- Upper respiratory tract infection
- Orthostatic hypotension
- Syncope
Drug Interactions
- Potent CYP3A4 inhibitors increase alfuzosin exposure significantly; contraindicated
- Other alpha-blockers or antihypertensive agents may cause additive hypotensive effects
- PDE5 inhibitors (e.g., sildenafil) co-administration can lead to symptomatic hypotension
Curated Content: Needs Vetting Before Put to Clinical Use